Afatinib
A targeted cancer medicine that blocks certain proteins called EGFR and HER2 that drive the growth of some cancers. By permanently binding to and shutting down these signaling proteins, afatinib helps slow or stop tumor growth in cancers where these targets are overactive.
Peso molecular
485,9400 g/mol
LogP
3,60
TPSA
88,60 Ų
Regla de cinco de Lipinski
Cumple
Áreas terapéuticas
Clases de fármacos
Mecanismo de acción
Irreversible covalent inhibitor of ErbB family (EGFR/HER1, HER2, HER4) tyrosine kinases.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Irreversible covalent inhibitor of ErbB family (EGFR/HER1, HER2, HER4) tyrosine kinases.
Estructura 2D
Cite this structure
Embed this structure
SMILES
CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1
InChI
InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1
Molecular Formula
C24H25ClFN5O3
HBD / HBA
2 / 8
Enlaces Rotables
8
Átomos Pesados
34
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
A targeted cancer medicine that blocks certain proteins called EGFR and HER2 that drive the growth of some cancers. By permanently binding to and shutting down these signaling proteins, afatinib helps slow or stop tumor growth in cancers where these targets are overactive.
Irreversible covalent inhibitor of ErbB family (EGFR/HER1, HER2, HER4) tyrosine kinases.
Key pharmacokinetic parameters for Afatinib: Half-life: 37 hours.
Yes, Afatinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
Related Drugs
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1173655. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 10184653. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="afatinib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/afatinib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/afatinib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/afatinib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="afatinib"></drugfyi-drug>